NCT07740083Active, not recruiting
The Effect of Patient Empowerment Learning (With AI) About Itching in Hemodylasis Patients.
The Effect of Artificial Intelligence-Supported Patient Empowerment Education on Itching in Patients With Chronic Kidney Disease Undergoing Hemodialysis
Source: ClinicalTrials.gov · Last updated 31 Jul 2026
Brief summary (registry, in English)
This study investigates whether artificial intelligence-supported patient education can reduce itching and improve patient empowerment in individuals with chronic kidney disease undergoing hemodialysis.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- First submitted
- 28 Jul 2026
- Start date
- 12 Jan 2025
- Primary completion date
- 28 Apr 2026
- Lead sponsor
- Izmir Tinaztepe University
- Diseases
- Chronic kidney disease
- NCT number
- NCT07740083
What you commit to
- Study type: Interventional
- Planned participants: 128
- From 12 Jan 2025 to the primary completion date, 28 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who got dementia and alzheimers.
Age
- Patients who is older than 65.
Other
- Patients who doesnt want to join the study.
Who the study is looking for
- Patients with CKD. Patients who have ithing symptom. Patients who is older than 18. Patients who takes hemodylasis treatment regularly and in order.
Age in the registry: 18 weeks to 65 weeks · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nursing Coordinator of this site? Confirm its status | Izmir | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.